Skip to main content
OpenTrials
Completed

NCT Number: NCT00911794

Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease

The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Lung Diseases COPD Chronic Disease Disease Attributes Dyspnea Fibrosis Lung Diseases Lung Diseases, Interstitial Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Pulmonary Fibrosis Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of COPD or Pulmonary Fibrosis
  • First time participants in Pulmonary Rehabilitation program

Exclusion criteria

  • Dementia
  • Prior significant psychiatric illness
  • Inability to complete the questionnaires
  • Inability cooperate with spirometry
  • Inability or to participate in outpatient follow-up over the six-month

Treatment and study plan

Disclosure Writing (Written Disclosure Therapy)

Other

Patients write about a stressful life experience

Other names: Written Disclosure Therapy

Neutral (Sham) Writing

Other

Patients write about neutral subjects

Other names: Sham Writing (Controls that wrote about neutral subjects)

Primary outcomes

  1. Dyspnea and quality of life

    Time frame: Two-month and six-month time

Secondary outcomes

  1. Six-minute walk distance

    Time frame: Two-month and six-month time

  2. Spirometry values (FEV1 and FVC)

    Time frame: Two-month and six-month time

Sponsors and collaborators

Lead sponsor

Winthrop University Hospital

Other

Collaborators

  • Stony Wold-Herbert Fund, Inc.

Registry information

Official study title

Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease

Important dates

Study start
2007
Primary completion
2008
Study completion
2009
First posted
Jun 2, 2009
Registry last updated
Jun 2, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.